As a University of British Columbia (UBC) spin-off, BirchBioMed provides a compelling investment opportunity for the life science/pharma investor.
Our patented groundbreaking anti-scar technology (FS2)
- The only antifibrotic (or anti-scarring) therapeutic on the market that prevents formation of scars and promotes the breakdown of existing scars
- A small molecule drug that attacks scarring on the molecular level without hindering wound healing
- Radically improves healing outcomes for burn survivors
- Dramatically reduces post-surgical treatment costs associated with scarring
- Numerous routes of administration (topical, oral, injection) as well as via medical devices (sutures, dressings, etc.)
- Poised to treat orphan diseases (i.e. Idiopathic lung fibrosis)
- Phase 1 clinical trial data demonstrates safe topical administration
Our patented, disruptive and highly regarded autoimmune technology (AI-001)
- Reverses type 1 diabetes and alopecia in gold-standard animal models
- Potential to replace all existing lifelong treatments for certain autoimmune diseases
- Requires only short-term protocols instead of lifelong treatments
- Manufacture and distribution would radically reduce costs of ongoing therapy;
